Skystar Bio-pharmaceutical (SKBI) Inactive 10-Q2012 Q1 Quarterly report

Filed: 15 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: advisor, anniversary, antibody, Article, awaiting, Bing, Certifying, Chen, Chengdu, compliance, confirmed, contributor, converge, cool, dampened, deadline, delist, detection, domestic, drug, eased, enforceable, engineering, enhanced, face, fairly, fermentation, FIFO, firm, fluctuate, food, foreseeable, frame, fulfill, growing, hearing, highly, husbandry, ii, immunosorbent, inspected, irrespective, issuable, kit, length, letter, levied, linked, markedly, marketplace, master, meaningfully, Mei, micro, MOA, monoclonal, Nasdaq, objective, OCI, offset, ofresjudicata, oil, opinion, oral, Panel, partial, partially, patent, penetrate, pet, postjudgment, prepayment, prohibiting, proposed, ratified, realignment, reclassification, reconciliation, redeliberate, reimbursement, respond, resume, resumed, retrospectively, reverse, routinely, Sanqiao, scope, segment, setoff, sharply, shift, shifted, softened, solicitation, split, strategy, successful, suggested, supersede, target, temporarily, therapeutic, thereto, Tiantai, tightening, tooling, trend, twelve, unable, uncertainty, undertaken, unpaid, unrecognized, volume, wife

Removed: achieving, advertising, arose, ASC, assert, assurance, attributable, audited, borrow, build, classification, close, combination, committee, comparable, complex, consistent, contractor, created, customer, derecognition, description, designing, desired, disclose, effort, eliminating, Emerging, escalate, expertise, feedback, footnote, Force, forma, freight, gain, goodwill, gradually, guidance, impaired, inherent, installment, interaction, mix, moderate, newly, nonrecurring, omitted, operated, paragraph, perform, permit, presenting, promotion, prorated, prospectively, qualify, qualitative, reining, relationship, Reorganize, representing, resigned, situation, sooner, step, supplemental, Supplementary, Task, tested, Tianjin, treated, unofficial, unsuccessful, utilization, vacated, vest, withdrawal, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SKBI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Skystar Bio-Pharmaceutical Company, (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weibing Lu, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated.

/s/ Weibing Lu

Weibing Lu

Chief Executive Officer

May 15, 2012

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.